Articles Related to chronic conditions
Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery
Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is the only FDA-approved drug labeled for prevention of preterm delivery. This drug is also available as a compounded product from licensed compounding pharmacies. This article reviews the FDA approval history and pharmacy compounding quality control data of 17-OHPC, as well as briefly discusses possible future pharmaceutical development strategies for 17-OHPC.
Editorial Board Members Related to chronic conditions
CARMEN CASTANEDA SCEPPA
Associate Professor
Department of Health Sciences
Bouvé College of Health Sciences
Northeastern University
United States
Department of Health Sciences
Bouvé College of Health Sciences
Northeastern University
United States